Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LGC Acquires Quotient’s Bioanalytical Business

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Acquisition will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector.

LGC and Quotient Bioresearch has announced that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.

Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.

The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.

Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences.

This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling.

The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.

The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.

Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”

Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quotient Clinical CEO Mark Egerton a Winner at UK EY Entrepreneur of the Year 2015 Awards
Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award.
Thursday, October 08, 2015
Quotient Clinical Reports Another Successful Year of Record Growth
Operating capacity set to more than double in response to rising demand.
Wednesday, May 13, 2015
Quotient Bioresearch Signs Strategic Alliance with Cambridge Research Biochemicals
Strategic partnership agreement to provide a joint consultancy solution for tritium peptide labelling, offering significant cost and time savings to customers.
Tuesday, July 05, 2011
Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines
Complementary Capabilities Will Cut Development Time and Expand Options for a Wide Range of Drugs.
Monday, November 15, 2010
Quotient Clinical and Bend Research Announce Collaboration to Accelerate Advancement of new Medicines
Complementary capabilities will cut development time and expand options for a wide range of drugs.
Thursday, November 11, 2010
Quotient Bioresearch to Highlight Integrated Early Stage Drug Development Platforms at FIP Pharmaceutical Sciences World Congress 2010
The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products with clinical testing.
Friday, October 15, 2010
Quotient Bioresearch’s new Radiochemistry Facility Fully Operational
The facility is now fully operational for shipments of radiolabelled products.
Thursday, July 29, 2010
Quotient Bioresearch Highlights Enhanced Benefits of 14C Radiolabelled Studies via Expert Webinar Series
The webinars will consist of scientific presentations from industry experts focused on a broad range of drug development activities.
Friday, April 02, 2010
Quotient Bioresearch extends agreement with GE Healthcare to complete transfer into new radiochemistry facility in Cardiff
An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed.
Monday, January 18, 2010
Quotient Bioresearch Presents Posters at European Bioanalysis Forum
The posters present aspects of best practice in validation and method development.
Tuesday, December 01, 2009
Quotient Delivers new Insight into Safety and Efficacy of Cardiovascular, Diabetes and Obesity Drugs
Data from Quotient Bioresearch’s new extended lipid marker screen for assessing drug safety and efficacy was presented at the Institute of Biomedical Sciences (IBMS) annual congress in Birmingham (UK) this week (28 – 30 September 2009).
Thursday, October 01, 2009
Quotient Bioresearch Announce Collaboration with Clinical Reference Laboratory
The Collaborators will jointly offer clinical laboratory and other specialist testing services to support the two Group’s clients world wide.
Tuesday, August 25, 2009
Quotient Clinical Receives MHRA Supplementary Accreditation
Accreditation qualifies Quotient Clinical to perform FIH studies for low molecular weight chemical entities and biologics.
Friday, July 10, 2009
High-throughput Biomarker Analysis Delivers Maximum Information from Each Sample
Quotient Bioresearch highlights its new multiplexed assays at Biomarker World Congress 2009.
Thursday, June 11, 2009
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories
The Charles River facility will combine with Pharmaceutical Profiles to form a new strategic business unit, Quotient Clinical.
Thursday, May 21, 2009
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!